Global Leading Market Research Publisher QYResearch announces the release of its latest report “Diabetic Gastroparesis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032” . Leveraging over 19 years of industry expertise and a database exceeding 100,000 reports, QYResearch provides authoritative analysis trusted by more than 60,000 clients worldwide across critical sectors including Pharmaceuticals, Medical Care, and Medical Devices & Consumables. This report delivers a crucial roadmap for pharmaceutical executives, medical device manufacturers, healthcare investors, and diabetes care specialists navigating the complex and growing market for a serious diabetic complication.
The global market for Diabetic Gastroparesis was estimated to be worth US$ 2,302 million in 2024 and is forecast to reach a readjusted size of US$ 3,310 million by 2031, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period 2025-2031. This steady growth occurs against a backdrop of a global pharmaceutical market where drug expenditure reached approximately US$ 1.48 trillion in 2022 (excluding COVID-related expenses), with projections of 3%-6% annual growth, and a U.S. market alone spending about US$ 629 billion on medicines. For endocrinologists, gastroenterologists, and patients, the core challenge is managing a debilitating and often overlooked complication of a global epidemic. Diabetes type 1 and type 2 are among the most common chronic diseases worldwide, affecting millions. One of the serious disorders associated with long-term diabetes is gastroparesis, a condition characterized by the delayed emptying of the stomach in the absence of a physical blockage. The primary cause is damage to the vagus nerve—a key nerve controlling the digestive tract—resulting from diabetic neuropathy. When blood glucose levels remain high over a prolonged period, they can injure this nerve, reducing or eliminating the stomach’s ability to contract and move food into the small intestine. This leads to a range of debilitating symptoms including nausea, vomiting, early satiety, bloating, and abdominal pain, severely impacting quality of life and nutritional status. The marked increase in the prevalence of diabetes, especially in developing countries like China, India, Brazil, and other Asian nations, is directly driving a rise in diabetic neuropathy and consequently, the incidence of diabetic gastroparesis worldwide, creating a growing and underserved patient population.
Defining the Condition and its Treatment Landscape
Diabetic gastroparesis is a disorder of gastric motility resulting from diabetes-induced nerve damage. As detailed in the QYResearch report, its diagnosis typically involves ruling out other causes and using imaging techniques such as ultrasound and X-ray, often accompanied by the intake of a radioisotope-labeled meal (like barium) to measure gastric emptying time. Hematological/blood tests and endoscopic techniques are also used.
The treatment market is segmented into two primary categories:
- Drugs: Pharmacological management is the first line of treatment. This includes several classes of drugs:
- Prokinetic agents: These drugs (e.g., metoclopramide, domperidone) enhance gastric motility by stimulating the muscles of the digestive tract. They are the mainstay of treatment but can have significant side effects, limiting long-term use.
- Antiemetics: Used to manage the debilitating symptoms of nausea and vomiting.
- Other emerging therapies: Research is ongoing into new drug classes that target different pathways involved in gastric motility.
- Surgical Treatment Products: For patients with severe, drug-refractory symptoms, interventional and surgical options are considered. These include:
- Gastric electrical stimulation (GES): A device, such as those from Medtronic, is implanted surgically and delivers mild electrical pulses to the stomach muscles to help control nausea and vomiting.
- Jejunostomy tube (J-tube) placement: In severe malnutrition, a feeding tube may be placed directly into the small intestine to bypass the stomach.
- Pyloromyotomy or pyloroplasty: Surgical procedures to widen the pylorus (the opening between the stomach and small intestine) to facilitate gastric emptying.
- Other supportive devices and interventions.
These products are distributed through various channels:
- Hospital Pharmacies: A primary channel for acute care, in-hospital dispensing, and surgical procedures.
- Retail Pharmacies: The main channel for patients filling ongoing prescriptions for antiemetics and prokinetic drugs.
- Online Pharmacies: A rapidly growing channel, offering convenience and often competitive pricing for chronic medications, increasingly important for patient adherence.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
(https://www.qyresearch.com/reports/4034110/diabetic-gastroparesis)
Key Industry Trends Reshaping the Market
Based on analysis of recent epidemiological data, drug development pipelines, and healthcare policy, four pivotal trends are defining the Diabetic Gastroparesis market through 2031.
1. The Global Diabetes Epidemic as the Primary Market Driver
The single most powerful driver is the relentless increase in the global prevalence of diabetes. The International Diabetes Federation projects continued growth in the number of adults living with diabetes, with the most significant increases in low- and middle-income countries. As the population of diabetics grows, so does the pool of patients at risk for long-term complications like diabetic neuropathy and, consequently, gastroparesis. This direct link between the underlying disease and the complication creates a structural, long-term growth trajectory for the market. Improved diabetes management can delay but not entirely prevent these complications, ensuring a steady patient pool for years to come. The rising health awareness and aging population trends noted in the Global Use of Medicines 2023 report further underscore this demand.
2. Unmet Need and the Quest for Novel, Safer Therapies
The current pharmacological options for diabetic gastroparesis are limited and often unsatisfactory. The primary prokinetic agent, metoclopramide, carries a black box warning from the FDA due to the risk of tardive dyskinesia (a serious movement disorder), limiting its long-term use. This significant unmet need is driving pharmaceutical R&D. Companies like Evoke Pharma have developed new formulations (e.g., a nasal spray) of existing drugs to improve tolerability or ease of use. Others are exploring novel mechanisms of action, such as ghrelin receptor agonists and motilin receptor agonists, which may offer improved efficacy and safety profiles. Success in this area could unlock significant market value and provide patients with much-needed better options.
3. The Role of Medical Devices in Advanced Disease Management
For patients with severe, drug-refractory symptoms, surgical treatment products like gastric electrical stimulators offer a critical option. The market for these devices is driven by the lack of effective pharmacological alternatives. Medtronic’s Enterra therapy is a well-established example. Innovation in this space is focused on developing less invasive devices, improving stimulator technology for better symptom control, and identifying patient selection criteria to ensure optimal outcomes. The convergence of device therapy with pharmacological management represents a comprehensive approach to severe disease.
4. Shifting Dynamics in Pharmaceutical Pricing and Access
The pharmaceutical market is operating in an environment of increasing pricing pressure, particularly in the U.S. The Inflation Reduction Act (IRA) , which allocates funds to reduce prescription drug prices, is reshaping the landscape for many chronic disease medications. The impact of patent expirations and generic or biosimilar competition, as noted in the Global Use of Medicines 2023 report, will also affect the diabetic gastroparesis market. Companies developing new, branded therapies must demonstrate clear clinical superiority to justify premium pricing in this increasingly cost-conscious environment. The growing role of online pharmacies also adds a layer of price transparency and competition, potentially affecting margins for retail and hospital pharmacy channels.
Market Segmentation and Strategic Outlook
The market is strategically segmented by product type and by distribution channel:
- By Type (Drugs vs. Surgical Treatment Products): Drugs represent the larger market share by volume, serving the broad patient population with first-line therapy. Surgical treatment products represent a smaller, higher-value segment for patients with severe, refractory disease, with significant growth potential as technology improves.
- By Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Hospital pharmacies are a key channel for acute care and surgical procedures. Retail pharmacies are the primary channel for chronic medication refills. Online pharmacies are the fastest-growing channel, driven by convenience and the chronic nature of the disease.
Exclusive Insight: The next major strategic frontier is the development of truly integrated care pathways that combine advanced diagnostics, better pharmacotherapies, and minimally invasive device interventions. We are seeing early research into using wireless motility capsules for more accurate and convenient diagnosis, moving beyond the cumbersome gastric emptying scan. There is also growing interest in the role of the gut microbiome in gastric motility and the potential for microbiome-based therapies. Furthermore, the application of neuromodulation techniques beyond GES, such as non-invasive vagus nerve stimulation, is an area of active investigation. This could offer a less invasive alternative for some patients. The ultimate goal is a personalized approach to diabetic gastroparesis, where treatment is tailored to the patient’s specific symptom profile, severity, and underlying pathophysiology. Companies like Abbott Laboratories, Boston Scientific Corporation, and C. R. Bard, Inc. are well-positioned to contribute to this evolution with their expertise in devices and diagnostics.
For pharmaceutical executives, medical device leaders, and healthcare investors, the strategic implication is clear. The diabetic gastroparesis market is a growing, underserved niche within the broader diabetes complication landscape. The rising global tide of diabetes ensures a steady increase in the addressable patient population. Success requires navigating a challenging regulatory and pricing environment, investing in innovation to address the significant unmet need for safer, more effective therapies, and developing integrated solutions that span the continuum of care from diagnosis to advanced intervention. Companies featured in the QYResearch report—from pharmaceutical giants like Sanofi, Pfizer, Teva, Novartis, and Janssen to specialized players like Evoke Pharma, Vanda Pharmaceuticals, and device leaders like Medtronic—are at various stages of addressing this complex and important condition.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
